Observational studyAmerican journal of hematology2017
Recognition of early mortality in multiple myeloma by a prediction matrix.
Observational study in American journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01081028 (Connect® MM- The Multiple Myeloma Disease Registry), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Connect® MM- The Multiple Myeloma Disease Registry
Who cites it
23 citing papers in PubMed.
- Trial
- High Prevalence of Acquired Platelet Secretion Defects in Multiple Myeloma.Hamostaseologie · 2026Article
- Early mortality in multiple myeloma patients with renal impairment: a nested case-control study.BMC nephrology · 2026Article
- Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.International journal of hematology · 2026Article
- Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
- Advanced disease and CD8Frontiers in immunology · 2025Article
- LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.Haematologica · 2024Article
- Article
- Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison.Cureus · 2023Article
- A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.Cancer · 2023Article
- Eastern Cooperative Oncology Group,Frontiers in microbiology · 2023Article
- Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).British journal of haematology · 2022Article
- IntestinalCancers · 2022Article
- Establishment and Validation for Predicting the Death of Multiple Myeloma among Whites.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study.Blood cancer journal · 2021Article
- [A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients.Frontiers in oncology · 2021Article
- Connect MM Registry as a national reference for United States multiple myeloma patients.Cancer medicine · 2020Observational
- Development of a prognostic model for overall survival in multiple myeloma using the ConnectBritish journal of haematology · 2019Observational
- Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.European journal of haematology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early mortality (EM; death ≤ 6 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%-14%. Causes of death included infections/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r-ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma-specific factors, are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients treated with novel agents in the Connect MM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.